Home » Stocks » NOVN

Novan, Inc. (NOVN)

Stock Price: $1.27 USD 0.27 (27.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $1.20 -0.07 (-5.51%) Jan 15, 7:57 PM
Market Cap 141.51M
Revenue (ttm) 5.23M
Net Income (ttm) -19.58M
Shares Out 133.69M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $1.27
Previous Close $1.00
Change ($) 0.27
Change (%) 27.00%
Day's Open 1.14
Day's Range 1.09 - 1.45
Day's Volume 107,466,430
52-Week Range 0.22 - 1.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 2 days ago

NEW YORK, Jan. 13, 2021 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

GlobeNewsWire - 1 week ago

MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of ...

GlobeNewsWire - 3 weeks ago

– Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing –

GlobeNewsWire - 1 month ago

– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 –

PRNewsWire - 1 month ago

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiducia...

GlobeNewsWire - 2 months ago

– T rading on Nasdaq Capital Market is expected to begin on November 5, 2020 –

GlobeNewsWire - 2 months ago

– Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 –

GlobeNewsWire - 2 months ago

- Live moderated video webcast discussion between members of management and Key Opinion Leader, John Browning, MD, FAAD, FAAP, MBA on Tuesday October 27th at 12:00 PM ET - Live moderated video...

GlobeNewsWire - 3 months ago

- F irst demonstration of antiviral effect of nitric oxide -based medicine against SARS-CoV-2 in an in vitro model that mimics the human airway epithelium

GlobeNewsWire - 3 months ago

- John M. Gay , V ice P resident , Finance and Corporate Controller with over 20 years of financial and accounting experience appointed as Chief Financial Officer

GlobeNewsWire - 4 months ago

- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 -

GlobeNewsWire - 4 months ago

- Live video webcast with President and CEO, Paula Brown Stafford, on Monday, September 14th at 4:00 PM EDT -

GlobeNewsWire - 4 months ago

- Topline results targeted for Q2 2021, less than a year away -

GlobeNewsWire - 4 months ago

- Clinical sites actively enrolling patients -

GlobeNewsWire - 5 months ago

MORRISVILLE, N.C., July 28, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced an expanded role of Paula Brown Stafford, President and Chief E...

GlobeNewsWire - 5 months ago

MORRISVILLE, N.C., July 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2020 Annua...

GlobeNewsWire - 6 months ago

MORRISVILLE, N.C., June 25, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company anticipates that its current cash position will be ...

GlobeNewsWire - 6 months ago

MORRISVILLE, N.C., June 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, the Company’s President and Chief Executi...

GlobeNewsWire - 8 months ago

MORRISVILLE, N.C., April 30, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has received meeting minutes from the April 1, 202...

GlobeNewsWire - 8 months ago

MORRISVILLE, N.C., April 20, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that it has engaged H.C. Wainwright & Co., LLC (“H.C. Wainwright & ...

Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for April 6th

Other stocks mentioned: CHWY, FRO, TNK
GlobeNewsWire - 9 months ago

MORRISVILLE, N.C., April 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that the Company has conducted its Type C meeting with the U.S. Foo...

Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for April 2nd

Other stocks mentioned: AYTU, DHT, EURN
Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for March 30th

Other stocks mentioned: FTSV, MRNA, VIRT
GlobeNewsWire - 9 months ago

MORRISVILLE, N.C., March 26, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced registered direct...

GlobeNewsWire - 9 months ago

MORRISVILLE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institu...

GlobeNewsWire - 9 months ago

MORRISVILLE, N.C., March 23, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced data from the prospectively planned safety evaluation through Week ...

Zacks Investment Research - 10 months ago

Inside the top-ranked stocks that have been exhibiting rising P/E ratios.

Other stocks mentioned: CFMS, KL, LONE, UEC
Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for March 11th

Other stocks mentioned: STMP, VNET, ZM
GlobeNewsWire - 10 months ago

MORRISVILLE, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company’s previously announced underwritten publ...

GlobeNewsWire - 10 months ago

MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten publi...

GlobeNewsWire - 10 months ago

MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ: NOVN) today announced that it intends to offer and sell a combination of shares of its co...

GlobeNewsWire - 10 months ago

MORRISVILLE, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has received approximately $1.0 million funding fro...

GlobeNewsWire - 11 months ago

MORRISVILLE, N.C., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today provided an update on several aspects of its Phase 3 B-SIMPLE program (B-SIMPL...

Market Watch - 1 year ago

Shares of Novan Inc. novn fell 72% in premarket trading on Friday after the biotechnology company said Thursday that its experimental treatment for molluscum contagiosum, a type of skin infect...

GlobeNewsWire - 1 year ago

MORRISVILLE, N.C., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq:NOVN) today announced that Paula Brown Stafford, currently President and Chief Operating O...

Zacks Investment Research - 1 year ago

Novan (NOVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

MORRISVILLE, N.C., Oct. 18, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has submitted a request for a pre-IND meeting with ...

GlobeNewsWire - 1 year ago

MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company’s Phase 2 molluscum study, designed to evaluate top...

GlobeNewsWire - 1 year ago

MORRISVILLE, N.C., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has received a grant from the U.S. Department of D...

GlobeNewsWire - 1 year ago

MORRISVILLE, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Compensation Committee of Novan’s Board of Directors grant...

GlobeNewsWire - 1 year ago

MORRISVILLE, N.C., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement...

GlobeNewsWire - 1 year ago

MORRISVILLE, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced the appointment of Michelle Patterson as Vice President of Project ...

About NOVN

Novan, Inc., a clinical development-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage dermatology product candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal na... [Read more...]

Industry
Biotechnology
IPO Date
Sep 21, 2016
CEO
Paula Stafford
Employees
24
Stock Exchange
NASDAQ
Ticker Symbol
NOVN
Full Company Profile

Financial Performance

In 2019, Novan's revenue was $4.90 million, a decrease of -18.28% compared to the previous year's $5.99 million. Losses were -$30.38 million, 3.89% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Novan stock is "Buy" and the 12-month stock price forecast is 2.75.

Price Target
$2.75
Analyst Consensus: Buy